ELOX - エロックス・ファ―マシュ―ティカルズ (Eloxx Pharmaceuticals Inc.) エロックス・ファ―マシュ―ティカルズ

 ELOXのチャート


 ELOXの企業情報

symbol ELOx
会社名 Eloxx Pharmaceuticals Inc (エロックス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Eloxx Pharmaceuticals Inc. formerly Sevion Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. The Company’s lead product candidate is ELX-02 is an optimized aminoglycoside designed to restore full-length functional proteins. The ELX-02 which is in Phase I clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. As part of clinical program the Company has completed a Phase Ia single ascending dose study in Israel and Belgium. The Company also intends to advance one or more additional molecules from its drug product candidate library toward clinical development.   エロックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がんや免疫疾患に対する治療の開発・商業化に従事する。同社候補薬は細胞ベ―スのアレイ化抗体やキメラソ―ム・ナノケ―ジを含む。また、免疫疾患や炎症性疾患の病因であるKv1.3イオンチャネルや、がんの進行に関する分子を標的とする治療を開発する。本社はマサチュ―セッツ州ウォルサム。   
本社所在地 950 Winter Street Waltham MA 02451 USA
代表者氏名 Robert E. Ward ロバートE.ウォード
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 858-909-0749
設立年月日 36161
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 15人
url www.senesco.com
nasdaq_url https://www.nasdaq.com/symbol/elox
adr_tso
EBITDA EBITDA(百万ドル) -40.95794
終値(lastsale) 14.91
時価総額(marketcap) 519728008.8
時価総額 時価総額(百万ドル) 522.51660
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 459.10460
当期純利益 当期純利益(百万ドル) -41.16942
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eloxx Pharmaceuticals Inc revenues was not reported. Net loss totaled to $22M. Results are not comparable due to year end change.

 ELOXのテクニカル分析


 ELOXのニュース

   CF Foundation Awards Up to $2M to Eloxx Pharmaceuticals for Additional Support of Phase 2 Clinical Studies of Potential Therapy for Nonsense Mutations  2021/01/13 14:00:00 Business Wire
BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations. In 2019, the Foundation provided Eloxx with an award of up to $1.6 million to support the development of ELX-02 in the U.S. This additional funding will provide continued support for a Phase 2 proof-of-concept cli
   80 Biggest Movers From Yesterday  2020/12/18 09:47:14 Benzinga
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS ) shares climbed 473.7% to close at $33.96 on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma shares gained around 8% on Wednesday after the company priced its IPO at $5.5 per share. MingZhu Logistics Holdings Ltd (NASDAQ: YGMZ ) shares surged 336.4% to close at $17.50. Wunong Net Technology Company Limited (NASDAQ: WNW ) shares climbed 88.2% to close at $122.50 after jumping 440% on Wednesday. The company, on Tuesday, priced its IPO at $5 per share. Nxt-ID, Inc. (NASDAQ: NXTD ) gained 54.2% to close at $1.4250 after jumping around 90% on Wednesday. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 47.7% to close at $5.45 after the company issued regulatory update for IV Tramadol. Boqii Holding Limited (NYSE: BQ ) rose 46.1% to close at $7.00. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) gained 34.4% to close at $9.11. Vivos Therapeutics, earlier during the month, priced its IPO at $6 a share.
   Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Stocks News Feed  2020/11/18 16:30:00 Stocks News Feed
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx,… Read More »Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
   Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update  2020/11/05 21:01:00 GlobeNewswire
Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021 The independent Safety Review Committees for our…
   Comparing Eloxx Pharmaceuticals (ELOX) & Its Competitors  2020/10/23 11:19:22 Dakota Financial News
Eloxx Pharmaceuticals (NASDAQ: ELOX) is one of 41 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, valuation, risk, dividends and profitability. Analyst Ratings This is a summary of […]
   80 Biggest Movers From Yesterday  2020/12/18 09:47:14 Benzinga
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS ) shares climbed 473.7% to close at $33.96 on Thursday. Scopus BioPharma’s filing showed registration for 500,000 share common stock offering. Scopus Biopharma shares gained around 8% on Wednesday after the company priced its IPO at $5.5 per share. MingZhu Logistics Holdings Ltd (NASDAQ: YGMZ ) shares surged 336.4% to close at $17.50. Wunong Net Technology Company Limited (NASDAQ: WNW ) shares climbed 88.2% to close at $122.50 after jumping 440% on Wednesday. The company, on Tuesday, priced its IPO at $5 per share. Nxt-ID, Inc. (NASDAQ: NXTD ) gained 54.2% to close at $1.4250 after jumping around 90% on Wednesday. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) jumped 47.7% to close at $5.45 after the company issued regulatory update for IV Tramadol. Boqii Holding Limited (NYSE: BQ ) rose 46.1% to close at $7.00. Vivos Therapeutics, Inc. (NASDAQ: VVOS ) gained 34.4% to close at $9.11. Vivos Therapeutics, earlier during the month, priced its IPO at $6 a share.
   Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Stocks News Feed  2020/11/18 16:30:00 Stocks News Feed
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx,… Read More »Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
   Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update  2020/11/05 21:01:00 GlobeNewswire
Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021 The independent Safety Review Committees for our…
   Comparing Eloxx Pharmaceuticals (ELOX) & Its Competitors  2020/10/23 11:19:22 Dakota Financial News
Eloxx Pharmaceuticals (NASDAQ: ELOX) is one of 41 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, valuation, risk, dividends and profitability. Analyst Ratings This is a summary of […]
   Eloxx Pharmaceuticals (ELOX) vs. Its Peers Head to Head Contrast  2020/10/23 07:19:18 Dispatch Tribunal
Eloxx Pharmaceuticals (NASDAQ: ELOX) is one of 41 public companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends. Earnings & Valuation This table compares Eloxx […]
   Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Stocks News Feed  2020/11/18 16:30:00 Stocks News Feed
WALTHAM, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, is pleased to announce that Dr. Gregory Williams, Chief Executive Officer of Eloxx,… Read More »Eloxx Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
   Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial and Operating Results and Provides Business Update  2020/11/05 21:01:00 GlobeNewswire
Expect to report top line data from our Phase 2 cystic fibrosis clinical trials in the first half of 2021 The independent Safety Review Committees for our…
   Comparing Eloxx Pharmaceuticals (ELOX) & Its Competitors  2020/10/23 11:19:22 Dakota Financial News
Eloxx Pharmaceuticals (NASDAQ: ELOX) is one of 41 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, valuation, risk, dividends and profitability. Analyst Ratings This is a summary of […]
   Eloxx Pharmaceuticals (ELOX) vs. Its Peers Head to Head Contrast  2020/10/23 07:19:18 Dispatch Tribunal
Eloxx Pharmaceuticals (NASDAQ: ELOX) is one of 41 public companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends. Earnings & Valuation This table compares Eloxx […]
   Eloxx Pharmaceuticals (ELOX) vs. Its Peers Head-To-Head Survey  2020/10/22 14:21:57 Dakota Financial News
Eloxx Pharmaceuticals (NASDAQ: ELOX) is one of 41 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its rivals? We will compare Eloxx Pharmaceuticals to similar businesses based on the strength of its profitability, institutional ownership, dividends, valuation, earnings, analyst recommendations and risk. Valuation & Earnings This table […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エロックス・ファ―マシュ―ティカルズ ELOX Eloxx Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)